We serve Chemical Name:tnca CAS:6314-28-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:tnca
CAS.NO:6314-28-9
Synonyms:Benzo[b]thiophene-2-carboxylic acid;1-Benzothiophene-2-carboxylic acid;MFCD00051636;2-Benzothiophenecarboxylic Acid;tnca
Molecular Formula:C9H6O2S
Molecular Weight:178.208
HS Code:2934999090
Physical and Chemical Properties:
Melting point:238-243 °C
Boiling point:376.2±15.0 °C at 760 mmHg
Density:1.4±0.1 g/cm3
Index of Refraction:1.717
PSA:65.54000
Exact Mass:178.008850
LogP:3.98
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Benzo[b]thiophene-2-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,tnca physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzo[b]thiophene-2-carboxylic acid Use and application,MFCD00051636 technical grade,usp/ep/jp grade.
Related News: Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037. tnca manufacturer That’s four days earlier than it had initially planned. Delta’s last China-bound flight left on Saturday, February 1, and its final returning flight from China to the United States leaves on Sunday. tnca supplier China has asked the European Union for help in buying urgently needed medical supplies from its member countries, the China��s official Xinhua news agency said on Saturday. tnca vendor China has asked the European Union for help in buying urgently needed medical supplies from its member countries, the China��s official Xinhua news agency said on Saturday. tnca factory The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting.
